ENOV ENOVIS CORPORATION

Enovis Introduces DynaNail Helix™ – a New Twist on Hindfoot Fusions

Enovis Introduces DynaNail Helix™ – a New Twist on Hindfoot Fusions

Designed with our patented and proven NiTiNOL technology, DynaNail Helix™ revolutionizes dynamic compression in foot & ankle fusion

Wilmington, DE, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Enovis Corporation (NYSE: ENOV), an innovation-driven medical technology company, announces the introduction of the DynaNail Helix™, the latest addition to the DynaNail® family and Enovis’ expansive suite of foot and ankle products. DynaNail Helix is designed to achieve sustained dynamic compression for subtalar fusion with an innovative, anatomically friendly design and simple, screw-like insertion.

Leveraging the same groundbreaking NiTiNOL compressive element technology from other DynaNail systems, the DynaNail Helix is smaller, easy to use, and comes with expanded indications.

“This is the same NiTiNOL technology used in the DynaNail intramedullary system. It provides sustained compression across the fusion site, which traditional screws cannot do,” said Dr. Christopher Hirosei, a foot and ankle orthopedic surgeon based in Boise, Idaho. “The Enovis DynaNail Helix NiTiNOL implants are as easy to use as traditional screws.” 

DynaNail Helix’s NiTiNOL compressive element comes pre-stretched and pre-loaded on a disposable nail guide for maximum efficiency. Like a screw, its threads allow for easy insertion. There are no transverse screws, eliminating the need for orthopedic surgeons to stretch the compressive element manually.

“The flexible, pseudo elastic NiTiNOL element that DynaNail Helix offers is unlike typical static fixation devices that are available on the market. Not only does DynaNail Helix offer intraoperative manual compression, but it also allows for up to 4mm of post-operative compression in response to bone resorption or settling,” said Gary Justak, President of Enovis Foot & Ankle. “This sustained compression is designed to give patients a better chance at healing faster, with fewer complications.”

The DynaNail Helix is one of several new products introduced by Enovis Foot & Ankle this year with active, adaptive healing technology designed to improve patient outcomes across the continuum of care.

For more information on the new DynaNail Helix, visit .

About Enovis

Enovis Corporation (NYSE: ENOV) is an innovation-driven, medical technology growth company dedicated to developing clinically differentiated solutions that generate measurably better patient outcomes and transform workflows. Powered by a culture of continuous improvement, global talent and innovation, the Company’s extensive range of products, services, and integrated technologies fuels active lifestyles in orthopedics and beyond. For more information about Enovis, please visit .

MK-10295






i Dr. Hirose is a paid consultant at Enovis.



Attachment



Media Contact:
Megan Foltz
Enovis
(609) 680-0996
 
EN
17/11/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ENOVIS CORPORATION

 PRESS RELEASE

Enovis to Participate in Upcoming Investor Conferences

Enovis to Participate in Upcoming Investor Conferences Wilmington, DE, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that its management team will participate in the following investor conferences: Canaccord Genuity 45th Annual Growth Conference on Wednesday, August 13th at 8:30 a.m. Eastern Time.Wells Fargo Healthcare Conference on Wednesday, September 3rd at 2:15 p.m. Eastern Time.Baird 2025 Global Healthcare Conference on Wednesday, September 10th at 3:10 p.m. Eastern Time. A link to the l...

 PRESS RELEASE

Enovis Announces Second Quarter 2025 Results

Enovis Announces Second Quarter 2025 Results Continued commercial momentum with second-quarter sales growth of 7% on a reported basisSecond-quarter Reconstructive sales grew 11% year-over-year on a reported basis  Wilmington, DE, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (“Enovis” or “the Company”) (NYSE: ENOV), an innovation-driven medical technology growth company, today announced its financial results for the second quarter ended July 4, 2025. The Company will host an investor conference call and live webcast to discuss these results today at 8:30 am ET. Second Quarter 2...

 PRESS RELEASE

Enovis to Host Second Quarter 2025 Results Conference Call on August 7...

Enovis to Host Second Quarter 2025 Results Conference Call on August 7th Wilmington, DE, July 08, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, announced that it will host an investor conference call and live webcast to discuss its second quarter 2025 financial results on Thursday, August 7th, 2025, at 8:30 a.m. Eastern Time and issue an earnings press release earlier that morning. A presentation related to the call, as well as a webcast, can be accessed from the "Investors" section of Enovis' website at . Conference C...

 PRESS RELEASE

Enovis to Participate in Upcoming Investor Conferences

Enovis to Participate in Upcoming Investor Conferences Wilmington, DE, June 06, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that its management team will participate in the following investor conferences: Goldman Sachs 46th Annual Global Healthcare Conference: Ben Berry, Chief Financial Officer, will participate in a fireside chat on Tuesday, June 10th at 2:00 p.m. Eastern Time.Citizens Medical Devices and Healthcare Services Forum: Ben Berry, Chief Financial Officer, will participate in investor meet...

 PRESS RELEASE

Enovis Announces First Quarter 2025 Results

Enovis Announces First Quarter 2025 Results Continued commercial momentum with first-quarter sales growth of 8% on a reported basis and strong adjusted EBITDA margin expansion First-quarter Reconstructive sales grew 11% year-over-year on a reported basis Appointed Damien McDonald as CEO, effective May 12th, 2025 Wilmington, DE, May 08, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (“Enovis” or “the Company”) (NYSE: ENOV), an innovation-driven medical technology growth company, today announced its financial results for the first quarter ended April 4, 2025. The Company will host an ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch